吉西他滨(dFdC)与放疗联合是一有效的肿瘤治疗方法。大量实验证明,吉西他滨在体外和体内都是有效的放射增敏剂,但由于其对正常组织的毒性增加,临床使用时必须小心。迄今为止已观察到放射增敏的相关机制,这些实验结果为临床上根据肿瘤的生物学特性制订出治疗患者的方案提供了重要依据。在某些肿瘤的Ⅰ期和Ⅱ期临床试验中,吉西他滨与放疗联合获得了明显的治疗效果。 Gemcitabine (dFdC) in combination with radiotherapy is an effective oncology treatment. Numerous experiments have demonstrated that gemcitabine is a potent radiosensitizer both in vitro and in vivo, but caution must be exercised in clinical use because of its increased toxicity to normal tissues. Up to now, the mechanism of radiosensitization has been observed. These experimental results provide an important basis for clinically developing a scheme for treating patients according to the biological characteristics of the tumor. In some tumor stage I and II clinical trials, gemcitabine combined with radiotherapy achieved significant therapeutic effect.